Share this post on:

product name Related Bcl-2 products


Description: ABT-737 is  a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in enzymatic assays, respectively;  It does not inhibit Mcl-1, Bcl-B or Bfl-1 etc. Currently under Phase 2 clinical study. ABT-737 has shown single-agent activity against lymphoma and small-cell lung cancer as well as substantial antimyeloma activity both in vitro and in vivo.

References: Cancer Res. 2007 Feb 1;67(3):1176-83.; Cell Death Differ. 2013 Jan;20(1):57-63. 



Molecular Weight (MW)

813.43
Formula

C42H45ClN6O5S2
CAS No.

852808-04-9
Storage

-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)

DMSO:    100 mg/mL (122.93 mM)
Water:     <1 mg/mL (slightly soluble or insoluble)
Ethanol:  <1 mg/mL
Solubility (In vivo)

30% Propylene glycol, 5% Tween 80, 65% D5W: 30mg/mL

other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19395491

General In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at 30 mg/kg and extended survival of mice.
Animal model Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
Formulation 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
Dosages 20 and 30 mg/kg
Administration For intraperitoneal (i.p.) every day
Reference Konopleva M, et al. Cancer Cell, 2006, 10(5), 375-388.

Calicheamicin